Page last updated: 2024-12-06
2-phenoxyphenol
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
2-Phenoxyphenol, also known as o-phenoxyphenol, is an organic compound with the formula C12H10O2. It is a white solid that is soluble in organic solvents. 2-phenoxyphenol is a fungicide that is used to protect plants from fungal diseases. It is also used as an intermediate in the synthesis of other chemicals. The compound is synthesized through a variety of methods, including the reaction of phenol with bromobenzene in the presence of a base. 2-phenoxyphenol is a potent inhibitor of the enzyme cytochrome P450, which is involved in the metabolism of many drugs and toxins. This compound has been studied for its potential applications in agriculture and medicine. Research has shown that it exhibits fungicidal and bactericidal properties. It is also being investigated for its potential to treat cancer and other diseases.'
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 75491 |
| CHEMBL ID | 148515 |
| CHEBI ID | 39261 |
| SCHEMBL ID | 260447 |
Synonyms (38)
| Synonym |
|---|
| 2-phenoxy-phenol |
| 2-phenoxyphenol |
| phenol, 2-phenoxy- |
| BIONET2_001265 |
| o-phenoxyphenol |
| 2417-10-9 |
| 2-hydroxydiphenyl ether |
| CHEBI:39261 , |
| HMS1367J11 |
| CHEMBL148515 |
| AKOS005084057 |
| 2-phenoxylphenol |
| bdbm36537 |
| pt51 |
| unii-kvi8n9886n |
| kvi8n9886n , |
| FT-0648308 |
| AM20030427 |
| SCHEMBL260447 |
| 1W-0639 |
| phenoxyphenol |
| 54774-79-7 |
| mfcd00093034 |
| 2-phenoxybenzenol |
| P-2980 |
| CS-W019370 |
| 2-hydroxyphenyl phenyl ether |
| phenoxyphenol, o- |
| phenol, o-phenoxy- |
| 2-phenoxyphenol # |
| DTXSID00178879 |
| phenol,2-phenoxy- |
| phenol, phenoxy- |
| A1-05146 |
| EN300-1868882 |
| Q27119795 |
| A918766 |
| CAA41710 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| phenoxyphenol | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (2)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI | Staphylococcus aureus subsp. aureus MRSA252 | Ki | 0.0189 | 0.0000 | 0.0095 | 0.0189 | AID1799923 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Other Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Fatty acid-binding protein, intestinal | Homo sapiens (human) | K1 | 0.5000 | 0.5000 | 0.5000 | 0.5000 | AID71603 |
| Fatty acid-binding protein, intestinal | Homo sapiens (human) | K2 | 0.4000 | 0.4000 | 0.4000 | 0.4000 | AID71604 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (4)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| fatty acid metabolic process | Fatty acid-binding protein, intestinal | Homo sapiens (human) |
| long-chain fatty acid transport | Fatty acid-binding protein, intestinal | Homo sapiens (human) |
| intestinal lipid absorption | Fatty acid-binding protein, intestinal | Homo sapiens (human) |
| fatty acid transport | Fatty acid-binding protein, intestinal | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Molecular Functions (4)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| long-chain fatty acid transmembrane transporter activity | Fatty acid-binding protein, intestinal | Homo sapiens (human) |
| fatty acid binding | Fatty acid-binding protein, intestinal | Homo sapiens (human) |
| protein binding | Fatty acid-binding protein, intestinal | Homo sapiens (human) |
| long-chain fatty acid binding | Fatty acid-binding protein, intestinal | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Ceullar Components (4)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| cytosol | Fatty acid-binding protein, intestinal | Homo sapiens (human) |
| microvillus | Fatty acid-binding protein, intestinal | Homo sapiens (human) |
| apical cortex | Fatty acid-binding protein, intestinal | Homo sapiens (human) |
| cytosol | Fatty acid-binding protein, intestinal | Homo sapiens (human) |
| nucleus | Fatty acid-binding protein, intestinal | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Bioassays (16)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1799923 | Thermal Shift Assay from Article 10.1021/bi400413c: \\Rational Optimization of Drug-Target Residence Time: Insights from Inhibitor Binding to the Staphylococcus aureus FabI Enzyme-Product Complex.\\ | 2013 | Biochemistry, Jun-18, Volume: 52, Issue:24 | Rational optimization of drug-target residence time: insights from inhibitor binding to the Staphylococcus aureus FabI enzyme-product complex. |
| AID1799428 | Enzyme Inhibition Assay from Article 10.1021/cb800306y: \\Slow-onset inhibition of the FabI enoyl reductase from francisella tularensis: residence time and in vivo activity.\\ | 2009 | ACS chemical biology, Mar-20, Volume: 4, Issue:3 | Slow-onset inhibition of the FabI enoyl reductase from francisella tularensis: residence time and in vivo activity. |
| AID71605 | Ionisation constant for the compound | 2004 | Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3 | Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues. |
| AID1296789 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus OM481 clinical isolate after 18 to 20 hrs by liquid microdilution method | 2016 | Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9 | Minimum structural requirements for cell membrane leakage-mediated anti-MRSA activity of macrocyclic bis(bibenzyl)s. |
| AID1296788 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus N315 after 18 to 20 hrs by liquid microdilution method | 2016 | Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9 | Minimum structural requirements for cell membrane leakage-mediated anti-MRSA activity of macrocyclic bis(bibenzyl)s. |
| AID71603 | In vitro inhibitory activity against wild-type intestinal Fatty acid-binding protein (FabI) of Escherichia coli expressed as K1 | 2004 | Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3 | Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues. |
| AID1059056 | Bacteriostatic activity against methicillin-resistant Staphylococcus aureus at 4 times MIC by cell survival assay | 2013 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24 | Structure-anti-MRSA activity relationship of macrocyclic bis(bibenzyl) derivatives. |
| AID717875 | Antibacterial activity against methicillin-resistant Staphylococcus aureus OM584 by two-fold liquid microdilution method | 2012 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24 | Riccardin C derivatives as anti-MRSA agents: structure-activity relationship of a series of hydroxylated bis(bibenzyl)s. |
| AID1059061 | Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate OM584 by liquid microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24 | Structure-anti-MRSA activity relationship of macrocyclic bis(bibenzyl) derivatives. |
| AID1296790 | Antimicrobial activity against 2-phenoxyphenol/methicillin-resistant Staphylococcus aureus after 18 to 20 hrs by liquid microdilution method | 2016 | Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9 | Minimum structural requirements for cell membrane leakage-mediated anti-MRSA activity of macrocyclic bis(bibenzyl)s. |
| AID717874 | Antibacterial activity against methicillin-resistant Staphylococcus aureus OM481 by two-fold liquid microdilution method | 2012 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24 | Riccardin C derivatives as anti-MRSA agents: structure-activity relationship of a series of hydroxylated bis(bibenzyl)s. |
| AID1059057 | Bactericidal activity against methicillin-resistant Staphylococcus aureus at 4 times MIC by cell survival assay | 2013 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24 | Structure-anti-MRSA activity relationship of macrocyclic bis(bibenzyl) derivatives. |
| AID1059060 | Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate N315 by liquid microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24 | Structure-anti-MRSA activity relationship of macrocyclic bis(bibenzyl) derivatives. |
| AID1059062 | Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate OM481 by liquid microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24 | Structure-anti-MRSA activity relationship of macrocyclic bis(bibenzyl) derivatives. |
| AID69489 | Minimum inhibitory concentration against Escherichia coli was determined | 2004 | Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3 | Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues. |
| AID71604 | In vitro inhibitory activity against wild-type intestinal Fatty acid-binding protein (FabI) of Escherichia coli expressed as K2 | 2004 | Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3 | Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 17.97
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.97) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||